- Atrix Laboratories' Atridox, combining the company's Atrigelbiodegradable polymer with the antibiotic doxocycline, has proved effective in Phase III trials of periodontal disease. Results from the 758 patients who completed the nine-month study showed that Atridox produced an 11% improvement compared to scaling and root planing, and was twice as effective as oral hygiene. On this basis, Atrix plans to file New Drug Applications with the US and European authorites in the next few weeks.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze